Role of the Circulating Procoagulants Microparticles in the Hypercoagulability of MNP Ph1-

Completed

• Conditions: Myeloproliferative Neoplasm
• Interventions: Other: Blood sampling

• Registration Number: NCT02862366
• Lead Sponsor: Lille Catholic University

Brief Summary

Patients with myeloproliferative neoplasms Philadelphia chromosome negative (MPNsPh1-) such as Essential thrombocytosis (ET), Polycythemia vera (PV) and Primary Myelofibrosis (PMF) have a higher risk of arterial or deep-vein thrombosis. This is responsible for a significant increase in mortality (up to 31% of increase in thrombosis risk in ET). Cellular inflation and blood hyperviscosity, resulting from these diseases, fail to account for these thromboses, as more than 50% of thrombotic complications happen under adapted antineoplastic drug treatment.

These last years, cellular microparticles (MPs) have been shown to play a major role in thrombogenesis. MPs are generated by apoptosis or the activation of malignant cells, platelets, endothelial cells or monocytes. They are fragments of plasma membrane, smaller than 1 µm, rich in phosphatidylserine, which can express the tissue factor and serve as support for the coagulation factors. Increase in the plasma concentration of procoagulant platelet microparticles has been demonstrated in other thrombotic diseases (acute coronary syndrome, disseminated intravascular coagulation DIC, etc.). The working hypothesis is that platelet microparticles are involved in the hypercoagulability of MPNs patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-10
• Primary Completion: 2016-01-25
• Study Completion: 2016-01-25
• Study First Submitted: 2016-08-02
• Study First Submitted QC: 2016-08-08
• Study First Posted: 2016-08-11
• Status Verified: 2018-08
• Last Update Submitted: 2018-10-30
• Last Update Posted: 2018-10-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 128

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Primary Myelofibrosis (PMF)	Blood sampling	Blood sampling during routine visit
Essential thrombocytosis (ET)	Blood sampling	Blood sampling during routine visit
Polycythemia vera (PV)	Blood sampling	Blood sampling during routine visit

Primary Outcome Measures

Name	Time	Method
Comparison of the average number of microparticles detected by flow cytometry in all subgroup	Baseline

Trial Locations

Locations (3)

EFS; 🇫🇷 Lille, France

GHICL; 🇫🇷 Lille, France

CHRU Lille; 🇫🇷 Lille, France